查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1790245

美國藥物研發外包市場規模、佔有率和趨勢分析報告：按工作流程、藥物、服務、治療領域、最終用途和細分市場預測，2025-2023 年

U.S. Drug Discovery Outsourcing Market Size, Share & Trends Analysis Report By Workflow, By Drug, By Service, By Therapeutics Area, By End Use, And Segment Forecasts, 2025 - 203
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

市場規模和趨勢

預計 2024 年美國藥物研發外包市場價值將達到 24.9 億美元，2025 年至 2033 年期間的複合年成長率將達到 9.52%。

藥物研發外包市場受到以下因素的推動：對候選藥物的需求不斷增加、慢性病患病率上升、研發支出不斷增加、新的官民合作關係關係建立、對專業知識的需求以及複雜標靶治療的增加。

此外，許多生物製藥和製藥公司正在轉向合約研發外包（CRO）和合約研發生產外包（CDMO），以利用人工智慧、生物資訊學和高效能篩檢等先進技術。此外，缺乏強大內部能力的小型虛擬生物技術公司的興起也進一步推動了外包趨勢。

此外，個人化醫療和自適應開發框架的趨勢也推動了對外包藥物研發服務的需求。全球化、加速新藥申請（IND）週期的需求以及新興治療領域的湧現，持續推動外包成為關鍵的成長策略。

此外，個人化醫療的興起推動了美國藥物研發外包領域對適應性小規模製造的需求。隨著治療變得更加有針對性，特別是在腫瘤學、罕見疾病和基因治療等領域，傳統的大規模製造方法正在讓位給定製藥物開發策略，預計這將在預計的時間內推動市場成長。

委外研發機構(CRO) 和委外研發機構(CDRO) 已成為重要的合作夥伴，利用其模組化基礎設施、靈活的工作流程和快速的檢測方法開發。外包使生物製藥公司能夠協調藥物設計、患者分層和生物標記主導研究方面的差異，從而提高靈活性、成本效益和速度，將精準療法推向市場。

此外，人工智慧 (AI) 和機器學習 (ML) 在藥物研發領域的日益融合，正在徹底改變化合物識別、最佳化和檢驗的流程。 AI 簡化了標靶識別、藥物相似性評估以及分子交互作用建模，顯著縮短了早期研發的時間和成本。此外，ML 演算法能夠篩選從體學資料到臨床結果的大量資料集，從而發掘創新見解，並最大限度地降低候選化合物篩選的風險。

此外，美國生物製藥公司擴大將人工智慧解決方案納入其工作流程，並與專注於人工智慧的委外研發機構(CRO) 合作，以提高生產力，加快臨床實驗申請 (IND) 的進程，並提高複雜和罕見疾病治療開發的成功率。例如，2024 年 7 月，Exscientia plc 宣布與亞馬遜網路服務 (AWS) 合作，利用該雲端供應商的人工智慧和機器學習服務來增強其端到端藥物發現和自動化平台。預計這些因素將推動預期週期的成長。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章美國藥物研發外包市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/輔助市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 臨床試驗量分析（2024年）
    • 各地區臨床試驗總數
    • 臨床試驗總數（依階段）
    • 臨床試驗總數（依研究設計）
    • 按主要治療領域分類的臨床試驗總數
  • 定價模式分析
  • 科技
  • 市場分析工具
    • 波特五力分析
    • PESTEL 與 SWOT 分析
    • COVID-19影響分析

第4章：美國藥物研發外包市場：依工作流程進行的估算與趨勢分析

  • 美國藥物研發外包市場（依工作流程）：細分儀表板
  • 美國藥物研發外包市場（依工作流程）：波動分析
  • 按工作流程，2021-2033 年
  • 目標識別與篩檢
  • 對象檢驗和功能資訊科學
  • 潛在客戶資格審查和候選人最佳化
  • 臨床前開發
  • 其他

第5章：美國藥物研發外包市場：依藥物的估計與趨勢分析

  • 美國藥物研發外包市場（按藥物）：細分儀表板
  • 美國藥物研發外包市場（按藥物）：波動分析
  • 依藥物分類，2021-2033 年
  • 小分子
  • 高分子

第6章：美國藥物研發外包市場：按服務分類的估算與趨勢分析

  • 美國藥物研發外包市場（按服務）：細分儀表板
  • 美國藥物研發外包市場（按服務）：波動分析
  • 按服務分類，2021-2033 年
  • 化學服務
  • 生物服務

第7章：美國藥物研發外包市場（依治療領域、估價及趨勢分析）

  • 美國藥物研發外包市場（依治療領域）：細分儀表板
  • 美國藥物研發外包市場（依治療領域）：波動分析
  • 依治療領域，2021-2033
  • 呼吸系統
  • 疼痛和麻醉
  • 腫瘤學
  • 眼科
  • 血液學
  • 心血管系統
  • 內分泌
  • 胃腸道
  • 免疫調節
  • 抗感染
  • 中樞神經系統
  • 皮膚科
  • 泌尿生殖系統

第 8 章：美國藥物研發外包市場最終用途、估價與趨勢分析

  • 美國藥物研發外包市場（依最終用途）：細分儀表板
  • 美國藥物研發外包市場（依最終用途）：波動分析
  • 依最終用途，2021-2033 年
  • 製藥和生物技術公司
  • 學術機構

第9章 競爭態勢

  • 市場參與企業分類
  • 2024 年公司市場佔有率/估值分析
  • 公司簡介
    • Albany Molecular Research Inc.
    • EVOTEC
    • Laboratory Corporation of America Holdings
    • GenScript
    • Pharmaceutical Product Development, LLC
    • Charles River Laboratories
    • WuXi AppTec
    • Thermo Fisher Scientific Inc.
    • Dalton Pharma Services
    • Oncodesign
    • Jubilant Biosys
    • DiscoverX Corp.
    • QIAGEN
    • Eurofins SE
    • Syngene International Limited
    • Dr. Reddy Laboratories Ltd.
    • Pharmaron Beijing Co., Ltd.
    • TCG Lifesciences Pvt Ltd.
    • Domainex Ltd.

第10章 主要建議

Product Code: GVR-4-68040-281-9

Market Size & Trends:

The U.S. drug discovery outsourcing market size was estimated at USD 2.49 billion in 2024 and is projected to grow at a CAGR of 9.52% from 2025 to 2033. The market for drug discovery outsourcing is driven by growing demand for novel drug candidates, rising incidence of chronic diseases, increasing R&D expenditures, emerging new private-public partnerships, a need for specialized knowledge, and a growing array of complex and targeted therapies.

Besides, most of the biopharmaceutical and pharmaceutical companies are turning to CROs and CDMOs to leverage advanced technologies such as artificial intelligence, bioinformatics, and high-throughput screening. In addition, the rising number of small and virtual biotech companies, which often lack robust internal capabilities, further accelerates the trend toward outsourcing.

Moreover, shifting trends towards personalized medicine and adaptable development frameworks enhances the demand for outsourced discovery services. Globalization, the need for quicker time-to-IND submissions, and the emergence of new therapeutic areas are continuously driving outsourcing as a key strategy for growth.

In addition, the emergence of personalized medicine is driving the need for adaptable, small-batch production within the U.S. drug discovery outsourcing sector. As treatments become increasingly targeted, particularly in areas like oncology, rare diseases, and gene therapy, traditional mass production methods are shifting towards customized drug development strategies, which are expected to drive the market growth over the estimated time period.

Contract research organizations (CROs) and contract development and research organizations (CDROs) utilize a modular infrastructure, flexible workflows, and quick assay development are becoming vital partners. Outsourcing provides biopharma companies with the ability to navigate variability in drug design, patient stratification, and biomarker-driven studies, which in turn enhances their agility, cost-effectiveness, and speed in bringing precision therapies to market.

Furthermore, the growing integration of artificial intelligence (AI) and machine learning (ML) in drug discovery is transforming the process of identifying, optimizing, and validating compounds. AI streamlines target identification, assesses drug-likeness, and models molecular interactions, leading to significant reductions in early-stage R&D timelines and expenses. Besides, ML algorithms sift through extensive datasets ranging from omics data to clinical outcomes to reveal innovative insights and minimize risks in candidate selection.

In addition, biopharma companies in the U.S. are increasingly incorporating AI-driven solutions into their workflows or collaborating with AI-focused contract research organizations (CROs) to boost productivity, accelerate the path to Investigational New Drug (IND) applications, and enhance success rates in the development of treatments for complex and rare diseases. For instance, in July 2024, Exscientia plc mentioned Amazon Web Services expansion to use the AI & ML services of cloud providers to power the company's platform for end-to-end drug discovery and automation. Such factors are expected to drive the estimated time period.

U.S. Drug Discovery Outsourcing Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. drug discovery outsourcing market report based on workflow, drug, service, therapeutics area, end use, and country.

  • Workflow Outlook (Revenue, USD Million, 2021 - 2033)
  • Target Identification & Screening
  • Target Validation & Functional Informatics
  • Lead Identification & Candidate Optimization
  • Preclinical Development
  • Others
  • Drug Outlook (Revenue, USD Million, 2021 - 2033)
  • Small Molecules
  • Large Molecules
  • Service Outlook (Revenue, USD Million, 2021 - 2033)
  • Chemistry Services
  • Biology Services
  • Therapeutics Area Outlook (Revenue, USD Million, 2021 - 2033)
  • Respiratory system
  • Pain and Anesthesia
  • Oncology
  • Ophthalmology
  • Hematology
  • Cardiovascular
  • Endocrine
  • Gastrointestinal
  • Immunomodulation
  • Anti-infective
  • Central Nervous System
  • Dermatology
  • Genitourinary System
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Pharmaceutical & Biotechnology companies
  • Academic Institutes

Table of Contents

Chapter 1. Research Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Workflow
    • 1.2.2. Drug
    • 1.2.3. Service
    • 1.2.4. Therapeutics Area
    • 1.2.5. End Use
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information Or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis
    • 1.7.2. Value chain-based analysis
    • 1.7.3. Multivariate Analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Abbreviations
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Drug Discovery Outsourcing Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rising R&D cost in biopharmaceutical Industry
      • 3.2.1.2. Increasing access to specialized expertise
      • 3.2.1.3. Growing demand for outsourcing Services in Drug Development
      • 3.2.1.4. Increasing number of partnerships in U.S. Drug Discovery research
      • 3.2.1.5. Technological advancements in drug discovery
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Presence of open-source software packages for drug discovery
      • 3.2.2.2. High manufacturing costs coupled with high risk of drug failure
      • 3.2.2.3. Rising Data Security and IP Concerns
      • 3.2.2.4. Regulatory and Compliance Risks
  • 3.3. Clinical Trials Volume Analysis (2024)
    • 3.3.1. Total Number of Clinical Trials, By Region
    • 3.3.2. Total Number of Clinical Trials, By Phase
    • 3.3.3. Total Number of Clinical Trials, By Study Design
    • 3.3.4. Total Number of Clinical Trials, By Key Therapeutic Area
  • 3.4. Pricing Model Analysis
  • 3.5. Technology Landscape
  • 3.6. Market Analysis Tools
    • 3.6.1. Porter's Five Force Analysis
    • 3.6.2. PESTEL by SWOT Analysis
    • 3.6.3. COVID-19 Impact Analysis

Chapter 4. U.S. Drug Discovery Outsourcing Market: Workflow Estimates & Trend Analysis

  • 4.1. U.S. Drug Discovery Outsourcing Market, By Workflow: Segment Dashboard
  • 4.2. U.S. Drug Discovery Outsourcing Market, By Workflow: Movement Analysis
  • 4.3. U.S. Drug Discovery Outsourcing Market Estimates & Forecasts, By Workflow, 2021 - 2033 (USD Million)
  • 4.4. Target Identification & Screening
    • 4.4.1. Target Identification & Screening Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Target Validation & Functional Informatics
    • 4.5.1. Target Validation & Functional Informatics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Lead Identification & Candidate Optimization
    • 4.6.1. Lead Identification & Candidate Optimization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.7. Preclinical Development
    • 4.7.1. Preclinical Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.8. Others
    • 4.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Drug Discovery Outsourcing Market: Drug Estimates & Trend Analysis

  • 5.1. U.S. Drug Discovery Outsourcing Market, By Drug: Segment Dashboard
  • 5.2. U.S. Drug Discovery Outsourcing Market, By Drug: Movement Analysis
  • 5.3. U.S. Drug Discovery Outsourcing Market Estimates & Forecasts, By Drug, 2021 - 2033 (USD Million)
  • 5.4. Small Molecules
    • 5.4.1. Small Molecules Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Large Molecules
    • 5.5.1. Large Molecules Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Drug Discovery Outsourcing Market: Service Estimates & Trend Analysis

  • 6.1. U.S. Drug Discovery Outsourcing Market, By Service: Segment Dashboard
  • 6.2. U.S. Drug Discovery Outsourcing Market, By Service: Movement Analysis
  • 6.3. U.S. Drug Discovery Outsourcing Market Estimates & Forecasts, By Service, 2021 - 2033 (USD Million)
  • 6.4. Chemistry Services
    • 6.4.1. Chemistry Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Biology Services
    • 6.5.1. Biology Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. U.S. Drug Discovery Outsourcing Market: Therapeutics Area Estimates & Trend Analysis

  • 7.1. U.S. Drug Discovery Outsourcing Market, By Therapeutics Area: Segment Dashboard
  • 7.2. U.S. Drug Discovery Outsourcing Market, By Therapeutics Area: Movement Analysis
  • 7.3. U.S. Drug Discovery Outsourcing Market Estimates & Forecasts, By Therapeutics Area, 2021 - 2033 (USD Million)
  • 7.4. Respiratory system
    • 7.4.1. Respiratory System Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Pain and Anesthesia
    • 7.5.1. Pain and Anesthesia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Oncology
    • 7.6.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. Ophthalmology
    • 7.7.1. Ophthalmology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8. Hematology
    • 7.8.1. Hematology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.9. Cardiovascular
    • 7.9.1. Cardiovascular Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.10. Endocrine
    • 7.10.1. Endocrine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.11. Gastrointestinal
    • 7.11.1. Gastrointestinal Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.12. Immunomodulation
    • 7.12.1. Immunomodulation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.13. Anti-infective
    • 7.13.1. Anti-infective Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.14. Central Nervous System
    • 7.14.1. Central Nervous System Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.15. Dermatology
    • 7.15.1. Dermatology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.16. Genitourinary System
    • 7.16.1. Genitourinary System Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. U.S. Drug Discovery Outsourcing Market: End Use Estimates & Trend Analysis

  • 8.1. U.S. Drug Discovery Outsourcing Market, By End Use: Segment Dashboard
  • 8.2. U.S. Drug Discovery Outsourcing Market, By End Use: Movement Analysis
  • 8.3. U.S. Drug Discovery Outsourcing Market Estimates & Forecasts, By End Use, 2021 - 2033 (USD Million)
  • 8.4. Pharmaceutical & Biotechnology companies
    • 8.4.1. Pharmaceutical & Biotechnology companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5. Academic Institutes
    • 8.5.1. Academic Institutes Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Market Participant Categorization
  • 9.2. Company Market Share/Assessment Analysis, 2024
  • 9.3. Company Profiles
    • 9.3.1. Albany Molecular Research Inc.
      • 9.3.1.1. Company Overview
      • 9.3.1.2. Financial Performance
      • 9.3.1.3. Service Benchmarking
      • 9.3.1.4. Strategic Initiatives
    • 9.3.2. EVOTEC
      • 9.3.2.1. Company Overview
      • 9.3.2.2. Financial Performance
      • 9.3.2.3. Service Benchmarking
      • 9.3.2.4. Strategic Initiatives
    • 9.3.3. Laboratory Corporation of America Holdings
      • 9.3.3.1. Company Overview
      • 9.3.3.2. Financial Performance
      • 9.3.3.3. Service Benchmarking
      • 9.3.3.4. Strategic Initiatives
    • 9.3.4. GenScript
      • 9.3.4.1. Company Overview
      • 9.3.4.2. Financial Performance
      • 9.3.4.3. Service Benchmarking
      • 9.3.4.4. Strategic Initiatives
    • 9.3.5. Pharmaceutical Product Development, LLC
      • 9.3.5.1. Company Overview
      • 9.3.5.2. Financial Performance
      • 9.3.5.3. Service Benchmarking
      • 9.3.5.4. Strategic Initiatives
    • 9.3.6. Charles River Laboratories
      • 9.3.6.1. Company Overview
      • 9.3.6.2. Financial Performance
      • 9.3.6.3. Service Benchmarking
      • 9.3.6.4. Strategic Initiatives
    • 9.3.7. WuXi AppTec
      • 9.3.7.1. Company Overview
      • 9.3.7.2. Financial Performance
      • 9.3.7.3. Service Benchmarking
      • 9.3.7.4. Strategic Initiatives
    • 9.3.8. Thermo Fisher Scientific Inc.
      • 9.3.8.1. Company Overview
      • 9.3.8.2. Financial Performance
      • 9.3.8.3. Service Benchmarking
      • 9.3.8.4. Strategic Initiatives
    • 9.3.9. Dalton Pharma Services
      • 9.3.9.1. Company Overview
      • 9.3.9.2. Financial Performance
      • 9.3.9.3. Service Benchmarking
      • 9.3.9.4. Strategic Initiatives
    • 9.3.10. Oncodesign
      • 9.3.10.1. Company Overview
      • 9.3.10.2. Financial Performance
      • 9.3.10.3. Service Benchmarking
      • 9.3.10.4. Strategic Initiatives
    • 9.3.11. Jubilant Biosys
      • 9.3.11.1. Company Overview
      • 9.3.11.2. Financial Performance
      • 9.3.11.3. Service Benchmarking
      • 9.3.11.4. Strategic Initiatives
    • 9.3.12. DiscoverX Corp.
      • 9.3.12.1. Company Overview
      • 9.3.12.2. Financial Performance
      • 9.3.12.3. Service Benchmarking
      • 9.3.12.4. Strategic Initiatives
    • 9.3.13. QIAGEN
      • 9.3.13.1. Company Overview
      • 9.3.13.2. Financial Performance
      • 9.3.13.3. Service Benchmarking
      • 9.3.13.4. Strategic Initiatives
    • 9.3.14. Eurofins SE
      • 9.3.14.1. Company Overview
      • 9.3.14.2. Financial Performance
      • 9.3.14.3. Service Benchmarking
      • 9.3.14.4. Strategic Initiatives
    • 9.3.15. Syngene International Limited
      • 9.3.15.1. Company Overview
      • 9.3.15.2. Financial Performance
      • 9.3.15.3. Service Benchmarking
      • 9.3.15.4. Strategic Initiatives
    • 9.3.16. Dr. Reddy Laboratories Ltd.
      • 9.3.16.1. Company Overview
      • 9.3.16.2. Financial Performance
      • 9.3.16.3. Service Benchmarking
      • 9.3.16.4. Strategic Initiatives
    • 9.3.17. Pharmaron Beijing Co., Ltd.
      • 9.3.17.1. Company Overview
      • 9.3.17.2. Financial Performance
      • 9.3.17.3. Service Benchmarking
      • 9.3.17.4. Strategic Initiatives
    • 9.3.18. TCG Lifesciences Pvt Ltd.
      • 9.3.18.1. Company Overview
      • 9.3.18.2. Financial Performance
      • 9.3.18.3. Service Benchmarking
      • 9.3.18.4. Strategic Initiatives
    • 9.3.19. Domainex Ltd.
      • 9.3.19.1. Company Overview
      • 9.3.19.2. Financial Performance
      • 9.3.19.3. Service Benchmarking
      • 9.3.19.4. Strategic Initiatives

Chapter 10. Key Recommendations

List of Tables

  • Table 1 List of Tables
  • Table 2 List of Secondary Sources
  • Table 3 List of Abbreviations
  • Table 4 U.S. Drug Discovery Outsourcing Market Estimates and Forecasts, by Workflow, 2021 - 2033 (USD Million)
  • Table 5 U.S. Drug Discovery Outsourcing Market Estimates and Forecasts, by Drug, 2021 - 2033 (USD Million)
  • Table 6 U.S. Drug Discovery Outsourcing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 7 U.S. Drug Discovery Outsourcing Market Estimates and Forecasts, by Therapeutics Area, 2021 - 2033 (USD Million)
  • Table 8 U.S. Drug Discovery Outsourcing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Market formulation & validation
  • Fig. 6 Commodity flow analysis
  • Fig. 7 Value-chain-based sizing & forecasting
  • Fig. 8 QFD model sizing & forecasting
  • Fig. 9 Bottom-up approach
  • Fig. 10 Market snapshot
  • Fig. 11 Segment snapshot 1
  • Fig. 12 Segment snapshot 2
  • Fig. 13 Competitive landscape snapshot
  • Fig. 14 Parent market outlook, 2024 (USD Billion)
  • Fig. 15 Ancillary market outlook, 2024 (USD Billion)
  • Fig. 16 U.S. Drug Discovery Outsourcing Market Dynamics
  • Fig. 17 Porter's five forces analysis
  • Fig. 18 PESTEL analysis
  • Fig. 19 U.S. Drug Discovery Outsourcing Market: Workflow outlook and key takeaways
  • Fig. 20 U.S. Drug Discovery Outsourcing Market: Workflow movement analysis
  • Fig. 21 Target Identification & Screening Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 22 Target Validation & Functional Informatics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 23 Lead Identification & Candidate Optimization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 24 Preclinical Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 25 Other Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 26 U.S. Drug Discovery Outsourcing Market: Drug outlook and key takeaways
  • Fig. 27 U.S. Drug Discovery Outsourcing Market: Drug movement analysis
  • Fig. 28 Small Molecules Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 29 Large Molecules Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 30 U.S. Drug Discovery Outsourcing Market: Service outlook and key takeaways
  • Fig. 31 U.S. Drug Discovery Outsourcing Market: Service movement analysis
  • Fig. 32 Chemistry Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 Biology Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 34 U.S. Drug Discovery Outsourcing Market: Therapeutics Area outlook and key takeaways
  • Fig. 35 U.S. Drug Discovery Outsourcing Market: Therapeutics Area movement analysis
  • Fig. 36 Respiratory system Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 Pain and Anesthesia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 39 Ophthalmology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 40 Hematology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 41 Cardiovascular Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 Endocrine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 43 Gastrointestinal Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 Immunomodulation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 45 Anti-infective Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 Central NervoU.S. System Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 47 Dermatology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 48 Genitourinary System Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 U.S. Drug Discovery Outsourcing Market: End Use outlook and key takeaways
  • Fig. 50 U.S. Drug Discovery Outsourcing Market: End Use movement analysis
  • Fig. 51 Pharmaceutical & Biotechnology companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 52 Academic Institutes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 Key company categorization
  • Fig. 54 Service heat map analysis
  • Fig. 55 Strategic framework